January 4, 2011 -- Mingyuan Medicare Development Co. Ltd. will begin a clinical validation study of its C12A protein microarray, a quantitative test for twelve tumor markers. The C12A protein microarray is an updated version of Mingyuan’s flagship C-12 test. The new version replaces four markers to increase sensitivity and specificity. More details....
